[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100589388":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":24,"centralContacts":28,"locations":10,"responsibleParty":34,"collaborators":10,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":40,"acronym":10,"eligibilityCriteria":41,"healthyVolunteers":38,"sex":42,"minAge":43,"maxAge":44,"enrollmentInfo":45,"targetDuration":10,"studyType":48,"phases":10,"briefSummary":49,"conditions":50,"keywords":10,"overallStatus":54,"whyStopped":10,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":10},{"fullName":5,"class":6},"Shanghai Zhongshan Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"lung cancer-sleep disorders",null,"Lung cancer patients treated with PD1 immunotherapy were divided into sleep disorders and non-sleep disorders groups.",[13,14],"Other: PSQI","Other: PQSI",[16,20],{"type":6,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"PSQI","Prospective observational cohort study: Cohort o: Stratified according to baseline sleep disorder severity (PSQI score ≥7 vs. \\\u003C7).",[9],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"PQSI","PQSI-Sleep quality assessment scale",[9],[25],{"name":26,"affiliation":5,"role":27},"Zilong Liu","PRINCIPAL_INVESTIGATOR",[29],{"name":30,"role":31,"phone":32,"phoneExt":10,"email":33},"Pan Jiang","CONTACT","18201731016","jiang.pan@zs-hospital.sh.cn",{"type":35,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100589388","a-prospective-study-the-impact-of-sleep-disturbances-on-immunotherapy-in-patients-with-lung-cancer-100589388",false,"NCT06953765","A Prospective Study: the Impact of Sleep Disturbances on Immunotherapy in Patients With Lung Cancer","Inclusion Criteria:\n\nDiagnosis of non-small-cell lung cancer (stage II-IV) Age 18 and older Immune checkpoint inhibitor therapy (e.g., nivolumab, pembrolizumab, etc.) is planned.\n\nBe able to understand the study and provide informed consent\n\nExclusion Criteria:\n\nCoexisting serious mental illness (e.g., major depression, anxiety, etc.) Recent chemotherapy or radiotherapy Other serious comorbidities (e.g., heart disease, liver and kidney insufficiency)","ALL","18 Years","70 Years",{"count":46,"type":47},350,"ESTIMATED","OBSERVATIONAL","In recent years, immunotherapy has made significant progress in the treatment of lung cancer, especially immune checkpoint inhibitors (such as PD-1\u002FPD-L1 antibodies) against non-small cell lung cancer (NSCLC). However, there are significant individual differences in patient response to treatment. Studies have shown that sleep disorders may affect the function of the immune system, thereby affecting tumor progression and treatment response. Therefore, the aim of this study was to evaluate the impact of sleep disturbances on lung cancer patients receiving immunotherapy.",[51,52,53],"Lung Cancer (NSCLC)","Sleep Disorders, Circadian Rhythm","PD-1","NOT_YET_RECRUITING","2025-04-29",{"date":57,"type":58},"2025-05-01","ACTUAL",{"date":60,"type":47},"2025-06-01",{"date":62,"type":47},"2028-12-30",{"name":5,"class":6}]